Cytokinetics, Incorporated (CYTK) Earnings History
Annual and quarterly earnings data from 2002 to 2025
Loading earnings history...
CYTK EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
CYTK Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 88.5% | -695.4% | -891.6% |
| 2024 | -1737.2% | -2902.7% | -3191.1% |
| 2023 | -4284.1% | -6589.7% | -6988.6% |
| 2022 | -154.6% | -342.8% | -411.2% |
| 2021 | -127.1% | -264.5% | -305.7% |
Download Data
Export CYTK earnings history in CSV or JSON format
Free sign-in required to download data
Cytokinetics, Incorporated (CYTK) Earnings Overview
As of May 9, 2026, Cytokinetics, Incorporated (CYTK) reported trailing twelve-month net income of -$830M, reflecting -24.3% year-over-year growth. The company earned $-6.73 per diluted share over the past four quarters, with a net profit margin of -891.6%.
Looking at the long-term picture, CYTK's historical earnings data spans multiple years. The company achieved its highest annual net income of $25M in fiscal 2009.
Cytokinetics, Incorporated is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including MDGL (-$309M net income, -30.1% margin), KRYS ($225M net income, 52.6% margin), RCUS (-$369M net income, -142.9% margin), CYTK has room to improve margins relative to the peer group. Compare CYTK vs MDGL →
CYTK Earnings vs Peers
Earnings metrics vs comparable public companies
CYTK Historical Earnings Data (2002–2025)
24 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$785M | -33.2% | -$612M | $-6.54 | -891.6% | -695.4% |
| 2024 | -$590M | -12.0% | -$536M | $-5.26 | -3191.1% | -2902.7% |
| 2023 | -$526M | -35.3% | -$496M | $-5.45 | -6988.6% | -6589.7% |
| 2022 | -$389M | -80.6% | -$324M | $-4.33 | -411.2% | -342.8% |
| 2021 | -$215M | -69.2% | -$186M | $-2.80 | -305.7% | -264.5% |
| 2020 | -$127M | -4.6% | -$94M | $-1.97 | -228.0% | -168.3% |
| 2019 | -$122M | -14.5% | -$99M | $-2.59 | -452.9% | -368.0% |
| 2018 | -$106M | +16.8% | -$89M | $-1.95 | -337.4% | -282.3% |
| 2017 | -$128M | -876.7% | -$113M | $-2.59 | -955.9% | -848.3% |
| 2016 | $16M | +143.9% | $19M | $0.39 | 15.5% | 17.6% |
Full CYTK Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See CYTK's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CYTK Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CYTK vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCYTK — Frequently Asked Questions
Quick answers to the most common questions about buying CYTK stock.
Is CYTK growing earnings?
CYTK EPS fell to $-6.73, with earnings declining -24.3%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-830M.
What are CYTK's profit margins?
Cytokinetics, Incorporated net margin is -891.6%, with operating margin at -695.4%. Below-average margins reflect competitive or cost pressures.
How consistent are CYTK's earnings?
CYTK earnings data spans 2002-2025. The declining earnings trend is -24.3% YoY. Historical data enables comparison across business cycles.